390
Participants
Start Date
July 2, 2022
Primary Completion Date
November 20, 2026
Study Completion Date
April 20, 2027
Abatacept plus
"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
Placebo
Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Allegheny-Singer Research Institution, Pittsburgh
RECRUITING
Lehigh Valley Health Network, Bethlehem
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
MedStar Health Research Institute, Georgetown University, Washington D.C.
RECRUITING
Johns Hopkins, Baltimore
RECRUITING
University of West Virginia, Morgantown
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Franciscan Health, Indianapolis
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Aurora St Luke's Medical Center, Milwaukee
RECRUITING
Mayo Clinic, Rochester
RECRUITING
University of Chicago, Chicago
RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
University of Texas Southwestern, Dallas
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
University of Utah, Salt Lake City
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Robert Wood Johnson University Hospital, New Brunswick
RECRUITING
University of North Carolina Chapel Hill, Chapel Hill
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of Kentucky, Lexington
RECRUITING
Maine Health, Portland
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Boston Medical Center, Boston
RECRUITING
University of British Colombia, Vancouver
RECRUITING
McMaster University, Hamilton
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Massachusetts General Hospital
OTHER